Bicara Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Income StatementBalance SheetCash FlowRatios
Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Bicara Therapeutics Inc. (BCAX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022
Period EndingDec 2024Dec 2023Dec 2022
Operating Activities
Net Income-68.00-51.99-37.85
Depreciation & Amortization0.060.020.01
Stock Based Compensation7.401.900.81
Change in Working Capital-14.13-9.624.95
Change in Accounts Payable2.64-8.665.87
Change in Other Working Capital-0.0813.50-0.92
Other Operating Activities-0.0813.500.00
Net Cash from Operating Activities-74.75-45.63-32.08
Investing Activities
Capital Expenditures-0.07-0.59-0.19
Other Investing Activities0.060.000.00
Net Cash from Investing Activities-0.01-0.59-0.19
Financing Activities
Common Stock Issued332.430.150.16
Other Financing Activities1.600.000.00
Net Cash from Financing Activities334.03272.5031.70
Summary
Net Change in Cash259.27226.28-0.57
Cash at Beginning of Period230.444.164.73
Cash at End of Period489.71230.444.16
Free Cash Flow-74.82-46.21-32.27
Supplemental Disclosures
Income Taxes Paid0.000.000.00